2024Äê11ÔÂ1ÈÕ

µÏÍþÖƵÏÍþ¹ú¼Ê¼¯ÍÅÓÐÏÞ¹«Ë¾ (ÒÔϼò³Æ¡°µÏÍþÖƵÏÍþ¹ú¼Ê¡±£¬03692.HK)Ðû²¼£¬¹«Ë¾×ÔÖ÷Ñз¢µÄB7-H3°ÐÏò¿¹Ìå-µÏÍþ¹ú¼ÊÎïżÁªÎADC£©×¢ÉäÓÃHS-20093»ñÖйú¹ú¼ÒµÏÍþ¹ú¼ÊÆ·¼à¶½¹ÜÀí¾Ö£¨NMPA£©µÏÍþ¹ú¼ÊÆ·ÆÀÉóÖÐÐÄ£¨CDE£©Åú×¼ÄÉÈë¡°Í»ÆÆÐÔÖÎÁƵÏÍþ¹ú¼ÊÎ£¬ÄⶨÊÊӦ֢Ϊ¾­±ê×¼Ò»ÏßÖÎÁÆ£¨º¬²¬Ë«µÏÍþ¹ú¼Ê»¯ÁÆÁªºÏÃâÒߣ©ºó½øÕ¹µÄ¹ã·ºÆÚСϸ°û·Î°©£¨ES-SCLC£©¡£

2023Äê12Ô£¬µÏÍþÖƵÏÍþ¹ú¼ÊÓëGlaxoSmithKline Intellectual Property (No.4) Limited£¨GSK£©¶©Á¢Ðí¿ÉЭÒ飬ÊÚÓèGSKÈ«Çò¶ÀÕ¼Ðí¿É£¨²»º¬ÖйúÄڵء¢Ïã¸Û¡¢°ÄÃż°Ì¨Í壩£¬ÒÔ¿ª·¢¡¢Éú²ú¼°ÉÌÒµ»¯HS-20093£¨Òà³ÆGSK5764227)£¬¸ÃµÏÍþ¹ú¼ÊÎïÄ¿Ç°ÕýÓÉGSK¿ªÕ¹È«Çò¢ñÆÚÁÙ´²ÊÔÑé¡£2024Äê8Ô£¬GSKÐû²¼ÃÀ¹úʳƷµÏÍþ¹ú¼ÊÆ·¼à¶½¹ÜÀí¾Ö(FDA)ÊÚÓèGSK5764227Í»ÆÆÐÔÁÆ·¨È϶¨£¬ÓÃÓÚº¬²¬»¯ÁÆÆÚ¼ä»òÖ®ºó½øÕ¹µÄ£¨¸´·¢»òÄÑÖÎÐÔ£©ES-SCLC»¼ÕßÖÎÁÆ¡£

¹ØÓÚHS-20093

HS-20093ÊÇÒ»ÖÖÐÂÐÍB7-H3°ÐÏòADC£¬ÓÉÈ«ÈËÔ´¿¹B7-H3µ¥¿¹ÓëÍØÆËÒ칹øÒÖÖƼÁ(TOPOi)ÓÐЧÔغɹ²¼ÛÁ¬½Ó¶ø³É£¬Ä¿Ç°ÕýÔÚÖйú¿ªÕ¹ÓÃÓÚСϸ°û·Î°©µÄ¢óÆÚÁÙ´²Ñо¿£¬ÒÔ¼°ÈâÁö¡¢Í·¾±°©¡¢Ê³¹Ü°©¼°ÆäËûʵÌåÁöµÄ¶àÏî¢ñÆÚ¼°¢òÆÚÁÙ´²Ñо¿¡£

¹ØÓÚСϸ°û·Î°©

·Î°©ÊÇÈ«ÊÀ½ç×î³£¼ûµÄ°©Ö¢Ö®Ò»¡£ÔÚСϸ°û·Î°©»¼ÕßÖУ¬70%µÄ»¼Õß»¼Óй㷺Æڷΰ©£¬ÕâÒâζ×Å°©Ö¢ÒѾ­À©É¢µ½µ¥·Î»òË«·ÎºÍ/»òÉíÌåµÄÆäËû²¿Î»¡£ES-SCLCÊÇÒ»ÖÖÇÖÏ®ÐÔºÍÄÑÖÎÐÔ°©Ö¢£¬ÖÎÁÆÑ¡ÔñÓÐÏÞ£¬5ÄêÉú´æÂÊԼΪ3%¹¡£´ó¶àÊýES-SCLC»¼ÕßÔÚ³õ´ÎÖÎÁƺ󸴷¢£¬ÖÐλÊý¸´·¢ÐÔES-SCLC»¼Õß²ÉÓõ±Ç°±ê×¼»¤ÀíÖÎÁƵÄ×ÜÌåÉú´æÆÚΪ5-6¸öÔ²¡£

¹ØÓÚÍ»ÆÆÐÔÖÎÁÆÆ·ÖÖ

¸ù¾Ý¡¶¹ú¼ÒµÏÍþ¹ú¼ÊÆ·¼à¶½¹ÜÀí¾Ö¹ØÓÚ·¢²¼Í»ÆÆÐÔÖÎÁƵÏÍþ¹ú¼ÊÎïÉóÆÀ¹¤×÷³ÌÐò£¨ÊÔÐУ©µÈÈý¸öÎļþµÄ¹«¸æ¡·£¨2020ÄêµÚ82ºÅ£©£¬Í»ÆÆÐÔÖÎÁƵÏÍþ¹ú¼ÊÎï³ÌÐòÊÊÓ÷¶Î§Îª¡ª¡ªµÏÍþ¹ú¼ÊÎïÁÙ´²ÊÔÑéÆڼ䣬ÓÃÓÚ·ÀÖÎÑÏÖØΣ¼°ÉúÃü»òÕßÑÏÖØÓ°ÏìÉú´æÖÊÁ¿µÄ¼²²¡£¬ÇÒÉÐÎÞÓÐЧ·ÀÖÎÊֶλòÕßÓëÏÖÓÐÖÎÁÆÊÖ¶ÎÏà±ÈÓÐ×ã¹»Ö¤¾Ý±íÃ÷¾ßÓÐÃ÷ÏÔÁÙ´²ÓÅÊƵĴ´ÐµÏÍþ¹ú¼ÊµÈ¡£

Õë¶ÔÄÉÈëÍ»ÆÆÐÔÖÎÁƵÏÍþ¹ú¼ÊÎï³ÌÐòµÄµÏÍþ¹ú¼ÊÎCDEÓÅÏÈÅäÖÃ×ÊÔ´½øÐйµÍ¨½»Á÷£¬¼ÓÇ¿Ö¸µ¼²¢´Ù½øµÏÍþ¹ú¼ÊÎïÑз¢£»²¢ÇÒ¾­ÆÀ¹À·ûºÏÏà¹ØÌõ¼þµÄ£¬Ò²¿ÉÒÔÔÚÉêÇëµÏÍþ¹ú¼ÊÆ·ÉÏÊÐÐí¿ÉʱÌá³ö¸½Ìõ¼þÅú×¼ÉêÇëºÍÓÅÏÈÉóÆÀÉóÅúÉêÇë¡£

¹ØÓÚµÏÍþÖƵÏÍþ¹ú¼Ê

µÏÍþÖƵÏÍþ¹ú¼ÊÊÇÖйúÁìÏȵĴ´ÐÂÇý¶¯ÐÍÖƵÏÍþ¹ú¼ÊÆóÒµ£¬Öصã¹Ø×¢¿¹Ö×Áö¡¢¿¹¸ÐȾ¡¢ÖÐÊàÉñ¾­ÏµÍ³¡¢´úл¼°×ÔÉíÃâÒßµÈÖØ´ó¼²²¡ÖÎÁÆÁìÓò£¬ÖÂÁ¦ÓÚͨ¹ý³ÖÐø´´ÐÂÌá¸ßÈËÀàÉúÃüÖÊÁ¿¡£½ØÖÁ2024ÉÏ°ëÄ꣬¹«Ë¾ÒÑÉÏÊÐ7¿î´´ÐµÏÍþ¹ú¼Ê£¬ÐγÉÁ˷ḻµÄ²úÆ·¹ÜÏß¡£µÏÍþÖƵÏÍþ¹ú¼ÊÁ¬Ðø¶àÄêλ¾ÓÈ«ÇòÖƵÏÍþ¹ú¼ÊÆóÒµ°ÙÇ¿¡¢ÖйúÒ½µÏÍþ¹ú¼ÊÑз¢²úÆ·Ïß×î¼Ñ¹¤ÒµÆóҵǰ3Ç¿£¬Êǹú¼ÒÖصã¸ßм¼ÊõÆóÒµ¡¢¹ú¼Ò¼¼Êõ´´ÐÂʾ·¶ÆóÒµ¡£¹«Ë¾ÓÚ2019Äê6ÔÂÔÚÏã¸ÛÁª½»Ëù¹ÒÅÆÉÏÊУ¨¹ÉƱ´úÂ룺03692.HK£©¡£¸ü¶àÐÅÏ¢Çë·ÃÎÊ£º/¡£

ÉùÃ÷

µÏÍþÖƵÏÍþ¹ú¼Ê²»ÍƼöÈκÎδ»ñÅúµÏÍþ¹ú¼ÊƷʹÓûòδ»ñÅúÊÊÓ¦Ö¢ÓõÏÍþ¹ú¼Ê£¬±¾ÐÂΟåÖеÄÒ½ÁÆÐÅÏ¢½ö¹©ÐÅÏ¢ºÍÐÂÎű¨µÀʹÓ㬲»ÓÃÓÚ¹ã¸æÄ¿µÄ¡£²»Òª½«ÆäÓÃÓÚÒ½ÁƱ£½¡»òÕï¶Ï½¨Òé¡£

Ç°Õ°ÐÔ˵Ã÷£º

±¾ÐÂΟåÖ¼ÔÚÌṩ¹ØÓÚµÏÍþÖƵÏÍþ¹ú¼Ê¼¯ÍÅÓÐÏÞ¹«Ë¾¼°Æ丽Êô¹«Ë¾£¨°üÀ¨Æä×Ó¹«Ë¾£¬Í³³ÆΪ¡°µÏÍþÖƵÏÍþ¹ú¼Ê¡±£©µÄÐÅÏ¢¡£Ëü²»¹¹³É¶ÔµÏÍþÖƵÏÍþ¹ú¼Ê»òÈκÎͶ×ʽ¨ÒéµÄÐÅÏ¢Åû¶¡£

±¾ÐÂΟå°üº¬µÄÐÅÏ¢¿ÉÄÜ°üÀ¨ÓëµÏÍþÖƵÏÍþ¹ú¼ÊÒµÎñºÍ²úÆ·Ç°¾°¡¢¼Æ»®¡¢ÐÅÄî¡¢Ô¤ÆںͲßÂÔÏà¹ØµÄÇ°Õ°ÐÔÉùÃ÷¡£ÕâЩÉùÃ÷ÊÇ»ùÓÚÍƲâÐÔ¼ÙÉèµÄÔ¤²â£¬²¢²»±£Ö¤Î´À´µÄ±íÏÖ¡£ËüÃÇÊܵ½ÖîÈç¿Æѧ¡¢ÉÌÒµ¡¢ÕþÖΡ¢¾­¼Ã¡¢²ÆÎñ¡¢·¨ÂÉÒòËØÒÔ¼°¾ºÕù»·¾³ºÍÉç»áÌõ¼þµÈ·çÏպͲ»È·¶¨ÐÔµÄÓ°Ï죬ÕâЩÒòËغܶ඼ÊǵÏÍþÖƵÏÍþ¹ú¼ÊÎÞ·¨¿ØÖÆÇÒÄÑÒÔÔ¤²âµÄ£¬Òò´Ëʵ¼Ê½á¹û¿ÉÄÜÓë´Ë´¦ËùÊöÓÐÏÔÖø²îÒ죬ÇÒ¹ýÈ¥µÄ֤ȯ¼Û¸ñÇ÷ÊƲ»Ó¦×÷ΪδÀ´ÐÐÇéµÄÖ¸µ¼¡£Òò´Ë£¬Í¶×ÊÕßÔÚʹÓÃÕâЩÐÅÏ¢½øÐÐͶ×ʾö²ßʱӦ½÷É÷ÐÐÊ¡£¡°ÖÂÁ¦ÓÚ¡±¡°Ô¤ÆÚ¡±¡°ÏàÐÅ¡±¡°Ô¤²â¡±¡°Òâͼ¡±¡°Ô¤¼Æ¡±¡°¿ÉÄÜ¡±¡°½«¡±¡°Ó¦¸Ã¡±¡°¼Æ»®¡±¡°¼ÌÐø¡±¡°Ä¿±ê¡±¡°¿¼ÂÇ¡±¡°¹À¼Æ¡±¡°Ö¸µ¼¡±¡°Ç±ÔÚ¡±¡°×·Çó¡±ÒÔ¼°ÓÚÈκÎδÀ´¼Æ»®¡¢Ðж¯»òʼþµÄÌÖÂÛÖÐʹÓõÄÀàËÆ´ÊÓïºÍÊõÓ¾ù±íʾǰհÐÔÉùÃ÷¡£

µÏÍþÖƵÏÍþ¹ú¼Ê²»³Ðŵ»ò±£Ö¤Ç°Õ°ÐÔÐÅÏ¢µÄ׼ȷÐÔ¡¢¼°Ê±ÐÔ»òÍêÕûÐÔ£¬²¢ÇÒ²»³Ðµ£¸üлòÐÞ¶©ÕâЩǰհÐÔÉùÃ÷µÄÒåÎñ¡£ÎÞÂÛÊǵÏÍþÖƵÏÍþ¹ú¼Ê»¹ÊÇÆäÈκζ­Ê¡¢Ô±¹¤»ò´úÀíÈË£¬¾ù²»¶ÔÈκÎÖ¤Ã÷²»×¼È·»òÎÞ·¨ÊµÏÖµÄÇ°Õ°ÐÔÉùÃ÷¸ºÔð£¬Ò²²»¶ÔÒòÒÀÀµ±¾ÐÂΟåÖÐÌṩµÄÐÅÏ¢¶ø²úÉúµÄÈκÎËðʧ»òË𺦸ºÔ𣬰üÀ¨µ«²»ÏÞÓÚÖ±½Ó¡¢Å¼È»¡¢¼ä½Ó»ò³Í·£ÐÔµÄË𺦡£

±¾ÐÂΟåÖеÄËùÓÐÐÅÏ¢¾ùΪ·¢²¼Ö®ÈÕµÄ×îÐÂÐÅÏ¢¡£µÏÍþÖƵÏÍþ¹ú¼Ê²»³Ðµ£Òòз¢Õ¹¡¢Î´À´Ê¼þ»òÆäËûÇé¿ö¶ø¸üлòÐÞ¶©ÕâЩÐÅÏ¢µÄÔðÈΣ¬³ý·Ç·¨ÂÉÒªÇó¡£´ËÍ⣬µÏÍþÖƵÏÍþ¹ú¼Ê±£ÁôÔÚÈκÎʱºòδ¾­Í¨Öª¶Ô±¾ÐÂΟåµÄÈ«²¿»ò²¿·ÖÄÚÈݽøÐиü¸Ä¡¢¸üÕý»òÖжϵÄȨÀû¡£¶ÔÓÚÌرðÓëÉÏÊй«Ë¾ÓйصÄÐÅÏ¢£¬¹«Ë¾¹ÄÀøͶ×ÊÕ߲ο¼µÏÍþÖƵÏÍþ¹ú¼Ê£¨03692.HK£©µÄ¹«¸æºÍ²ÆÎñ±¨¸æ¡£

²Î¿¼ÎÄÏ×£º

1.SEER Explorer Surveillance Research Program, US National Cancer Institute, accessed 23 January 2024.

2.Topotecan USPI accessed 11 March 2024.